What Is MOG Antibody Disease? How It Differs From MS

MOG antibody disease, formally known as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), is an inflammatory condition of the central nervous system in which the immune system produces antibodies that target a protein called MOG on the outer surface of myelin, the insulating sheath around nerve fibers. Recognized as a distinct diagnosis only within the past decade, MOGAD was long lumped together with multiple sclerosis and another antibody-driven condition called neuromyelitis optica spectrum disorder (NMOSD). It has its own mechanisms of damage, its own patterns on brain and spinal imaging, and its own treatment considerations that set it apart from both.

What MOG Is and Why the Immune System Attacks It

MOG is a small transmembrane protein that sits on the outermost layer of the myelin sheath exclusively in the brain and spinal cord. Structurally, its exposed portion folds into a shape resembling an immune-system signaling molecule, which may partly explain why the immune system sometimes mistakes it for a target. Crystallography studies show that this exposed domain can pair up into dimers, consistent with a role as an adhesion molecule holding myelin layers together.¹ Structural work also reveals that the region of MOG recognized by demyelinating antibodies harbors a cavity resembling one used by the immune checkpoint molecule B7-2, hinting at why this protein is so immunologically provocative.²

When MOG antibodies bind their target, damage follows through several routes. The antibodies tag MOG-coated myelin for destruction by the complement system (a cascade of proteins that punch holes in cell membranes) and by immune cells that recognize the antibody’s tail end, a process called antibody-dependent cellular cytotoxicity. Beyond those two pathways, MOG antibodies also appear to disrupt the internal scaffolding of oligodendrocytes (the cells that make myelin) and to boost the activation of T cells that have infiltrated the brain and spinal cord.³ Experimental work teasing apart these mechanisms found that complement-driven damage and immune-cell-receptor-driven damage contribute roughly equally to demyelination, while the enhanced activation of T cells in the central nervous system depends specifically on the immune-cell receptor pathway rather than complement.⁴

How MOGAD Typically Presents

MOGAD announces itself through a handful of core clinical patterns, though the mix depends heavily on whether the patient is a child or an adult. Optic neuritis, inflammation of one or both optic nerves, is the single most common presentation. It accounts for roughly 40% of first attacks in children and closer to 56% in adults.⁵ MOG-associated optic neuritis has some distinctive features: it tends to involve both eyes, causes visible disc swelling, and on MRI produces long stretches of optic nerve inflammation predominantly in the front segments, often with inflammation of the nerve sheath (perineuritis) as well.⁶⁷

Transverse myelitis, inflammation across a segment of the spinal cord, is the second most common presentation, occurring in about a quarter of patients.⁸ On spinal MRI, MOGAD myelitis tends to produce long stretches of signal change with a distinctive pattern: a bright line running up and down the cord on side-view images, and an H-shaped pattern on cross-section, reflecting inflammation concentrated in the gray matter of the cord.⁹ The lower tip of the cord (the conus) is frequently involved as well.¹⁰

In children, acute disseminated encephalomyelitis (ADEM), a widespread brain inflammation that causes confusion and neurological deficits, is far more common than in adults, appearing in about 37% of pediatric cases versus under 6% of adult ones.¹¹ A less common but increasingly recognized presentation is cerebral cortical encephalitis, in which inflammation targets the brain’s outer cortex. A pediatric cohort study found encephalitis in 14% and ADEM in 31% of children who tested positive for MOG antibodies.¹² In severe pediatric cases, cortical encephalitis can produce bilateral swelling visible on MRI and critical neurological illness.¹³

Getting the Diagnosis Right

The cornerstone of diagnosing MOGAD is detecting MOG-IgG antibodies in the blood using a cell-based assay, a lab test that expresses the MOG protein on the surface of living or chemically fixed cells and then checks whether the patient’s serum antibodies bind to it. This matters because older detection methods produced unacceptable rates of false positives. In 2023, an international panel proposed formal diagnostic criteria built around three steps: identifying a core demyelinating event (such as optic neuritis, myelitis, or ADEM), confirming a positive MOG-IgG test, and excluding alternative diagnoses like MS or AQP4-positive NMOSD.¹⁴¹⁵

The type of cell-based assay influences reliability. A multicenter comparison found that live cell-based assays had superior positive predictive values compared to fixed cell assays. Specificity reached 100% at one live-cell center and ranged above 98% at the others, while all five false-positive results in the study occurred on fixed-cell platforms.¹⁶ In practice, many commercial labs use fixed assays, and real-world comparison shows that the two platforms agree about 93% of the time, with most disagreements occurring at low antibody titers.¹⁷ The international criteria account for this by requiring additional clinical or radiological supporting features when a positive result comes from a fixed assay without a reported titer.¹⁸

Low-positive results are the gray zone. A weakly positive test in someone without a classic demyelinating presentation should be interpreted cautiously, because false positives cluster at low titers. Clinicians weigh the titer alongside the clinical picture and MRI findings rather than treating the antibody test alone as a definitive answer.

How MOGAD Differs From MS and NMOSD

For years, many patients now recognized as having MOGAD were misdiagnosed with either MS or AQP4-positive NMOSD. The distinctions matter because treatments differ. On brain MRI, MS tends to produce lesions in characteristic locations: along the lateral ventricles, in the inferior temporal lobe, and in U-shaped fibers just beneath the cortex (so-called Dawson’s fingers). A multicenter study found that a set of brain lesion distribution criteria could correctly identify MS with about 91% sensitivity and distinguish it from MOG-antibody-positive NMOSD with about 95% specificity.¹⁹

When both conditions produce large, tumor-like (tumefactive) brain lesions, additional clues help. MOGAD tumefactive lesions are more often accompanied by headache and sleepiness, while MS tumefactive lesions tend to show features like a dark rim on T2 imaging, restricted diffusion, ring-shaped contrast enhancement, and dark signal on T1. Oligoclonal bands in spinal fluid, a hallmark of MS, were found in only 5% of MOGAD cases compared to 70% of MS cases, and the white cell count in spinal fluid was substantially higher in MOGAD.²⁰ Perhaps most telling, MOGAD tumefactive lesions were more likely to resolve completely on follow-up imaging, something rarely seen in MS.

Distinguishing MOGAD from AQP4-positive NMOSD is trickier on imaging alone since the two share broadly similar MRI features, though AQP4-NMOSD more commonly shows restricted diffusion in tumefactive lesions.²¹ In practice, the antibody tests themselves do most of the differentiating work: MOG-IgG versus AQP4-IgG. Testing for both is now standard when evaluating a suspected inflammatory demyelinating condition that does not fit the typical MS pattern.

Treating Acute Attacks

MOGAD attacks generally respond well to aggressive early treatment. High-dose intravenous corticosteroids (typically methylprednisolone) are the first-line therapy. Most patients improve substantially, though clinicians have learned that tapering steroids too quickly can trigger a rebound. When steroids alone are not enough, plasma exchange, which physically removes the circulating antibodies, and intravenous immunoglobulin (IVIg) are used as second-line options.²²

One of the practical lessons that has emerged is that MOGAD is often steroid-dependent. Patients feel much better on high-dose steroids, but symptoms flare when the dose drops. This pattern pushes many patients toward long-term maintenance therapy rather than an acute-treat-and-stop approach.

Preventing Relapses

Not everyone with MOGAD relapses. Some patients have a single attack and never experience another, while others follow a relapsing course. The challenge is figuring out who needs ongoing preventive treatment. Persistently positive MOG antibodies during remission are a strong signal: patients whose antibodies remain detectable are at substantially higher relapse risk than those who become seronegative.²³ A multicenter study found that MOG antibody titers above a certain threshold during remission were associated with over ten times the hazard of relapse, and that patients who seroconverted to negative experienced a 95% reduction in relapse rate.²⁴

For patients who do need ongoing therapy, the options include maintenance IVIg, mycophenolate mofetil, azathioprine, and rituximab. A retrospective study of 59 adults on maintenance IVIg found that the median relapse rate dropped from 1.4 attacks per year before treatment to zero on treatment. Dosing mattered: only 17% of patients receiving at least 1 g/kg every four weeks or more frequently relapsed, versus 50% of those on lower or less frequent doses.²⁵

An interesting wrinkle is that rituximab, a B-cell-depleting drug that works exceptionally well in AQP4-NMOSD, is less impressive against MOGAD. A retrospective comparison found that while rituximab reduced relapses, its performance lagged behind both maintenance IVIg and azathioprine.²⁶ A meta-analysis confirmed that rituximab does prevent relapses, but the effect is less dramatic than in NMOSD, reflecting real differences in the underlying immunology.²⁷ Traditional MS disease-modifying drugs appear to be outright ineffective, which underscores how biologically distinct MOGAD is from MS.

Long-Term Outlook and Visual Prognosis

The prognosis of MOGAD is generally more favorable than that of AQP4-NMOSD, though it is not uniformly benign. Because optic neuritis is so common, vision is the outcome patients worry about most. A five-year follow-up study found that visual acuity recovered almost fully in the vast majority of patients with MOG-associated optic neuritis, and long-term visual outcomes were as good as those in MS and substantially better than in AQP4-positive NMOSD.²⁸ A separate long-term cohort reported that 90% of patients maintained visual acuity of 20/40 or better in both eyes, though optic nerve thinning (atrophy) was almost universal, and about a third had persistent visual field deficits despite good central acuity.²⁹

Children tend to recover better than adults. In a large international comparison, only about 10% of children had significant disability at last follow-up compared to roughly 27% of adults.³⁰ That said, a subset of patients across all ages accumulates residual deficits, especially those who have many relapses or whose attacks involve extensive tissue injury. In a Chinese long-term follow-up cohort, about a third of patients retained some neurological deficit, most commonly visual impairment.³¹

Monitoring With Biomarkers

Beyond the MOG antibody itself, researchers are studying additional blood and spinal fluid markers that could help predict who is at risk for severe attacks or accumulating disability. Neurofilament light chain, a protein released when nerve fibers are damaged, and glial fibrillary acidic protein (GFAP), a marker of damage to supporting brain cells called astrocytes, both show promise. Early data link higher levels of these markers to more severe attacks, greater relapse risk, and worse long-term disability.³² These are not yet part of routine clinical care, but they could eventually help clinicians decide when to escalate preventive therapy.

Pregnancy and MOGAD

For women of childbearing age with MOGAD, pregnancy planning raises specific concerns. A two-center retrospective study tracking 22 pregnancies found encouraging results: no relapses occurred during pregnancy itself, and only two relapses occurred postpartum, both in a single patient who already had a steroid-dependent relapsing course. The average relapse rate was effectively zero during pregnancy and remained very low in the year afterward.³³ Over half of the pregnancies were exposed to disease-modifying therapy at conception, and most of those patients continued treatment into the postpartum period. Obstetric complications occurred in about a fifth of pregnancies, though the study was too small to determine whether MOGAD itself raised that risk. Still, the overall message is reassuring compared to some other autoimmune conditions, where pregnancy and the postpartum period are well-known relapse triggers.

Overlap With Anti-NMDA Receptor Encephalitis

A small but clinically important subset of patients has antibodies against both MOG and the NMDA receptor, the target in anti-NMDA receptor encephalitis, a condition that causes psychiatric symptoms, seizures, and movement disorders. This overlap syndrome is the most commonly documented pairing of neural autoantibodies and creates diagnostic confusion because the presentation can blend features of both diseases: demyelination typical of MOGAD alongside the behavioral and psychiatric features more characteristic of anti-NMDA receptor encephalitis.³⁴ In one series of anti-NMDA receptor encephalitis patients, MOG antibodies were detected in the majority of those who had coexisting demyelinating features.³⁵ Recognizing this overlap matters because treatment must address both antibody-driven processes.

The Clinical Trial Landscape

Until recently, all treatment data in MOGAD came from retrospective studies and case series. That is changing. Several phase 2 and 3 randomized controlled trials are now underway testing therapies specifically in MOGAD patients. The agents under investigation include tocilizumab and satralizumab (both targeting the interleukin-6 pathway), rozanolixizumab (which accelerates the clearance of IgG antibodies from the blood), and azathioprine in a more rigorous trial design. These trials go by names like MOGwAI, TOMATO, METEOROID, and cosMOG.³⁶ Rozanolixizumab is particularly interesting because its mechanism, reducing circulating IgG levels by blocking the neonatal Fc receptor, directly addresses the antibody-mediated nature of MOGAD. If these trials succeed, MOGAD would join AQP4-NMOSD in having approved, disease-specific therapies rather than relying on off-label repurposing of drugs developed for other conditions. For patients living with a relapsing course, these trials represent the most significant shift in their treatment options since MOGAD was first recognized as its own disease.